Pneumocystis Jirovecii Pneumonia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Pneumocystis Jirovecii Pneumonia Market Outlook

Thelansis’s “Pneumocystis Jirovecii Pneumonia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pneumocystis Jirovecii Pneumonia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pneumocystis Jirovecii Pneumonia Overview

Pneumocystosis, also known as Pneumocystis jiroveci pneumonia (PJP, previously referred to as Pneumocystis carinii pneumonia [PCP]), is an opportunistic infection primarily seen in individuals with impaired immunity. The causative agent of pneumocystosis is the Pneumocystis organism, which is commonly found in the lungs of both healthy humans and other mammals. The organism responsible for human disease is Pneumocystis jirovecii, a ubiquitous parasite present worldwide. The majority of children have antibodies to Pneumocystis by age 3-4, indicating prior exposure to the organism. In immunocompetent individuals, P. jirovecii typically does not cause disease. The symptoms of pneumocystosis are relatively non-specific and may include breathlessness, fever, and a nonproductive (dry) cough. These symptoms tend to develop over several weeks in individuals infected with HIV. Physical signs of pneumocystosis are also non-specific and may include increased respiratory and heart rates. Lung examination may reveal mild crackles and rhonchi in approximately 50% of patients. The diagnosis of pneumocystosis is typically based on the microscopic identification of P. jirovecii from bronchopulmonary (lung) secretions obtained through methods such as induced sputum, bronchoalveolar lavage, or lung biopsy. Among these methods, bronchoalveolar lavage is considered the most reliable diagnostic method. The treatment of choice for pneumocystosis is co-trimoxazole.

• The incidence of pneumocystosis was estimated to be 2.6 per 100,000 inhabitants per year. Approximately two-thirds of pneumocystosis cases occurred in males. Additionally, a significant proportion of patients diagnosed with pneumocystosis (PCP) are 50-75 years old.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: